JCT  Vol.4 No.6 , August 2013
Saporin Conjugated Monoclonal Antibody to the Transcobalamin Receptor TCblR/CD320 Is Effective in Targeting and Destroying Cancer Cells
ABSTRACT

Cobalamin uptake into cells is mediated by the CD320 receptor for transcobalamin-bound cobalamin. Optimum receptor expression is associated with proliferating cells and therefore, in many cancers this receptor expression is up regulated. Delivering drugs or toxins via this receptor provides increased targeting to cancer cells while minimizing toxicity to the normal tissues. Saporin conjugated monoclonal antibodies to the extracellular domain of TCblR were effectively internalized to deliver a toxic dose of Saporin to some cancer cell lines propagating in culture. Antibody concentration of 2.5 nM was effective in producing optimum inhibition of cell proliferation. The cytotoxic effect of mAb-Saporin appears to be dictated primarily by the level of receptor expression and therefore normal primary cells expressing low levels of CD320 were spared while tumor cell lines with higher CD320 expression were destroyed. Targeting the pathway for cellular uptake of vitamin B12 via the CD320 receptor with toxin-antibody conjugates appears to be a viable treatment strategy for certain cancers that over expresses this receptor.


Cite this paper
E. Quadros, Y. Nakayama and J. Sequeira, "Saporin Conjugated Monoclonal Antibody to the Transcobalamin Receptor TCblR/CD320 Is Effective in Targeting and Destroying Cancer Cells," Journal of Cancer Therapy, Vol. 4 No. 6, 2013, pp. 1074-1081. doi: 10.4236/jct.2013.46122.
References
[1]   E. V. Quadros, Y. Nakayama and J. M. Sequeira, “The Protein and the Gene Encoding the Receptor for the Cellular Uptake of Transcobalamin-Bound Cobalamin,” Blood, Vol. 113, No. 1, 2009, pp. 186-192. doi:10.1182/blood-2008-05-158949

[2]   E. V. Quadros, S. P. Rothenberg and E. A. Jaffe, “Endothelial Cells from Human Umbilical Vein Secrete Functional Transcobalamin II,” American Journal of Physiology, Vol. 256, No. 2, 1989, pp. C296-303.

[3]   E. V. Quadros, Y. Nakayama and J. M. Sequeira, “The Binding Properties of the Human Receptor for the Cellular Uptake of Vitamin B12,” Biochemical and Biophysical Research Communications, Vol. 327, No. 4, 2005, pp. 1006-1010. doi:10.1016/j.bbrc.2004.12.103

[4]   K. Takahashi, M. Tavassoli and D. W. Jacobsen, “Receptor Binding and Internalization of Immobilized Transcobalamin II by Mouse Leukaemia Cells,” Nature, Vol. 288, No. 5792, 1980, pp. 713-715. doi:10.1038/288713a0

[5]   T. Kishimoto, M. Tavassoli, R. Green and D. W. Jacobsen, “Receptors for Transferrin and Transcobalamin II Display Segregated Distribution on Microvilli of Leukemia L1210 Cells,” Biochemical and Biophysical Research Communications, Vol. 146, No. 3, 1987, pp. 1102-1108. doi:10.1016/0006-291X(87)90761-3

[6]   E. V. Quadros, “Advances in the Understanding of Cobalamin Assimilation and Metabolism,” British Journal of Haematology, Vol. 148, No. 2, 2010, pp. 195-204. doi:10.1111/j.1365-2141.2009.07937.x

[7]   J. Lindemans, A. C. Kroes, J. van Geel, J. van Kapel, M. Schoester, et al., “Uptake of Transcobalamin II-Bound Cobalamin by HL-60 Cells: Effects of Differentiation Induction,” Experimental Cell Research, Vol. 184, No. 2, 1989, pp. 449-460. doi:10.1016/0014-4827(89)90343-1

[8]   T. Amagasaki, R. Green and D. W. Jacobsen, “Expression of Transcobalamin II Receptors by Human Leukemia K562 and HL-60 Cells,” Blood, Vol. 76, No. 7, 1990, pp. 1380-1386.

[9]   C. A. Hall, P. D. Colligan and J. A. Begley, “Cyclic Activity of the Receptors of Cobalamin Bound to Transcobalamin II,” Journal of Cellular Physiology, Vol. 133, No. 1, 1987, pp. 187-191. doi:10.1002/jcp.1041330125

[10]   W. Jiang, Y. Nakayama, J. M. Sequeira and E. V. Quadros, “Characterizing Monoclonal Antibodies to Antigenic Domains of TCblR/CD320, the Receptor for Cellular Uptake of Transcobalamin-Bound Cobalamin,” Drug Delivery, Vol. 18, No. 1, 2011, pp. 74-78. doi:10.3109/10717544.2010.509745

[11]   E. V. Quadros, Y. Nakayama and J. M. Sequeira, “Targeted Delivery of Saporin Toxin by Monoclonal Antibody to the Transcobalamin Receptor, TCblR/CD320,” Molecular Cancer Therapeutics, Vol. 9, No. 11, 2010, pp. 3033-3040. doi:10.1158/1535-7163.MCT-10-0513

[12]   F. Stirpe, A. Gasperi-Campani, L. Barbieri, A. Falasca, A. Abbondanza, et al., “Ribosome-Inactivating Proteins from the Seeds of Saponaria officinalis L. (Soapwort), of Agrostemma githago L. (Corn Cockle) and of Asparagus officinalis L. (Asparagus), and from the Latex of Hura crepitans L. (Sandbox Tree),” Biochemical Journal, Vol. 216, No. 3, 1983, pp. 617-625.

[13]   A. Bolognesi, L. Polito, V. Farini, M. Bortolotti, P. L. Tazzari, et al., “CD38 as a Target of IB4 mAb Carrying Saporin-S6: Design of an Immunotoxin for ex Vivo Depletion of Hematological CD38+ Neoplasia,” Journal of Biological Regulators & Homeostatic Agents, Vol. 19, No. 3-4, 2005, pp. 145-152.

[14]   L. Polito, A. Bolognesi, P. L. Tazzari, V. Farini, C. Lubelli, et al., “The Conjugate Rituximab/Saporin-S6 Completely Inhibits Clonogenic Growth of CD20-Expressing Cells and Produces a Synergistic Toxic Effect with Fludarabine,” Leukemia, Vol. 18, No. 7, 2004, pp. 1215-1222. doi:10.1038/sj.leu.2403378

[15]   D. A. Kniss, Y. Xie, Y. Li, S. Kumar, E. A. Linton, et al., “ED(27) Trophoblast-Like Cells Isolated from First-Trimester Chorionic Villi Are Genetically Identical to HeLa Cells yet Exhibit a Distinct Phenotype,” Placenta, Vol. 23, No. 1, 2002, pp. 32-43. doi:10.1053/plac.2001.0749

[16]   B. A. Teicher and R. V. Chari, “Antibody Conjugate Therapeutics: Challenges and Potential,” Clinical Cancer Research, Vol. 17, No. 20, 2011, pp. 6389-6397. doi:10.1158/1078-0432.CCR-11-1417

[17]   M. A. Firer and G. Gellerman, “Targeted Drug Delivery for Cancer Therapy: The Other Side of Antibodies,” Journal of Hematology & Oncology, Vol. 5, 2012, p. 70. doi:10.1186/1756-8722-5-70

[18]   R. Ippoliti, E. Lendaro, I. D’Agostino, M. L. Fiani, D. Guidarini, et al., “A Chimeric Saporin-Transferrin Conjugate Compared to Ricin Toxin: Role of the Carrier in Intracellular Transport and Toxicity,” FASEB Journal, Vol. 9, No. 12, 1995, pp. 1220-1225.

[19]   E. V. Quadros, S. P. Rothenberg and P. McLoughlin, “Characterization of Monoclonal Antibodies to Epitopes of Human Transcobalamin II,” Biochemical and Biophysical Research Communications, Vol. 222, No. 1, 1996, pp. 149-154. doi:10.1006/bbrc.1996.0713

[20]   G. R. McLean, E. V. Quadros, S. P. Rothenberg, A. C. Morgan, J. W. Schrader, et al., “Antibodies to Transcobalamin II Block in Vitro Proliferation of Leukemic Cells,” Blood, Vol. 89, No. 1, 1997, pp. 235-242.

[21]   S. C. Lai, Y. Nakayama, J. M. Sequeira and E. V. Quadros, “Down-Regulation of Transcobalamin Receptor TCblR/ CD320 by siRNA Inhibits Cobalamin Uptake and Proliferation of Cells in Culture,” Experimental Cell Research, Vol. 317, No. 11, 2011, pp. 1603-1607. doi:10.1016/j.yexcr.2011.02.016

 
 
Top